Clinical trials
Breast Cancer Triple Negative clinical trials
Below are recruiting breast cancer triple negative clinical trials, each written for real people, not researchers. We’re tracking 433 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06225284RecruitingPhase 2
Chemotherapy with or without hormone drug for premenopausal TNBC
This trial tests whether adding a hormone-blocking drug (GnRH agonist) to standard chemotherapy before surgery helps premenopausal women with triple-negative breast cancer. It aims to improve treatment outcomes by targeting hormones that may fuel tumor growth.
TaipeiAges 18 years+ - NCT06230185Recruiting
Blood test to monitor treatment response in triple-negative breast cancer
This trial is testing whether a blood test can track how well chemotherapy is working in people with early-stage triple-negative breast cancer. You would provide blood samples before and during treatment, and the results may help your doctor understand your response better.
Tucson, ArizonaAges 18 years+ - NCT06238921RecruitingPhase 1/Phase 2
Study of two drugs and radiation for triple-negative breast cancer that spread to the brain
This trial tests adding the drugs sacituzumab govitecan and zimberelimab to targeted radiation therapy for people with triple-negative breast cancer that has spread to the brain. The goal is to see if this combination helps control the cancer longer.
Tampa, FloridaAges 18 years+ - NCT06240195Recruiting
Study of sacituzumab govitecan for advanced triple-negative breast cancer
This study is testing a drug called sacituzumab govitecan (SG) for people with advanced triple-negative breast cancer who have already had other treatments. The goal is to see how well the drug works and what side effects it causes, using your tumor samples to look for clues (biomarkers).
Rome, RomeAges 18 years+ - NCT06245889RecruitingPhase 2
PET-Guided Therapy for Triple-Negative Breast Cancer
This trial tests whether a special PET scan can help guide the best combination of chemotherapy and immunotherapy before surgery for patients with triple-negative breast cancer. It aims to personalize treatment and improve outcomes.
Baltimore, MarylandAges 18 years+ - NCT06246968RecruitingPhase 1
Pembrolizumab and Cryoablation for Breast Cancer
This trial is testing a combination of a freezing procedure (cryoablation) and an immunotherapy drug called pembrolizumab (Keytruda) for people with triple-negative breast cancer that has spread. The goal is to see if freezing the tumor helps the immune system fight the cancer better.
Basking Ridge, New JerseyAges 18 years+ - NCT06247449Recruiting
MRI screening for brain metastases in aggressive breast cancer
This trial uses an MRI scan to look for early signs of breast cancer spreading to the brain in people with certain aggressive breast cancer types (triple-negative or HER2-positive) that are stage IIb or III. The goal is to find and treat brain metastases earlier, before they cause symptoms.
Toronto, OntarioAges 18 years+ - NCT06259162Recruiting
LAG3 study in triple-negative breast cancer
This trial is studying a protein called LAG3 in triple-negative breast cancer. It is for people who will receive chemotherapy before surgery to see if LAG3 levels affect how well the treatment works.
SeoulAges Any age - NCT06273800Recruiting
Chemo timing and the menstrual cycle in breast cancer
This study tests whether the timing of chemotherapy during your menstrual cycle affects how well it works in triple-negative breast cancer. Women with regular periods who are about to start chemo before surgery may be eligible.
Amsterdam, North HollandAges 18–59 - NCT06279364RecruitingPhase 3
Testing SKB264 vs standard chemo for advanced triple-negative breast cancer
This trial tests a new drug called SKB264 against standard chemotherapy options for people with advanced triple-negative breast cancer who have not yet received chemotherapy for their advanced disease. The goal is to see if SKB264 works better than the usual treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06281210Recruiting
Test to skip breast surgery after chemo
This trial checks if a breast biopsy can confirm that chemo has destroyed all cancer cells, so you might avoid surgery altogether. It's for people with aggressive breast cancer types who responded well to chemotherapy.
Candiolo, TurinAges 18 years+ - NCT06291064RecruitingPhase 2
Chemotherapy study for Nigerian women with triple-negative breast cancer
This trial studies a standard chemotherapy treatment for Nigerian women with triple-negative breast cancer that has not spread widely. It aims to see how well the treatment works and how safe it is.
Ikeja, LagosAges 18–70 - NCT06300125Recruiting
Freezing small low-risk breast tumors without surgery
This trial tests cryoablation (freezing the tumor with a needle) as a way to treat small, low-risk breast cancers without surgery. It is for women 50 or older whose cancers are hormone-receptor-positive and haven't spread to lymph nodes.
MilanAges 50 years+ - NCT06305962RecruitingEarly Phase 1
Radioactive drug for advanced PD-L1 positive solid tumors
This trial tests a radioactive medicine (177Lu-anti-PD-L1 sdAb) that delivers radiation to cancer cells with PD-L1 protein, which is found on some solid tumors. It is for people whose cancer has spread or come back after standard treatments.
Kingswood, New South WalesAges 18 years+ - NCT06318507Recruiting
Gut Bacteria and Immunotherapy for Triple-Negative Breast Cancer
This study looks at how bacteria in your gut might affect the way your body responds to immunotherapy for triple-negative breast cancer. It focuses on women who are overweight or obese and are about to start treatment with pembrolizumab before surgery.
Baton Rouge, LouisianaAges 18 years+ - NCT06318897RecruitingPhase 2
Immunotherapy with chemo for early triple-negative breast cancer
This trial tests a combination of an immunotherapy drug (pembrolizumab) plus two chemotherapy drugs (carboplatin and paclitaxel) given before surgery for people with early-stage, triple-negative breast cancer. The goal is to see if this treatment helps shrink or eliminate the tumor before it's removed.
Houston, TexasAges 18 years+ - NCT06324240RecruitingPhase 1
Personalized vaccine plus immunotherapy for triple-negative breast cancer
This trial tests a personalized vaccine made from your tumor combined with immunotherapy drugs (pembrolizumab or ipilimumab) for triple-negative breast cancer. It aims to help your immune system recognize and attack cancer cells.
Atlanta, GeorgiaAges 18 years+ - NCT07020117RecruitingPhase 1
Study of AKY-1189 for advanced solid tumors
This trial tests a new radioactive drug, AKY-1189, for people with solid tumors that have spread or cannot be removed. It may help if other treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT07570524Recruiting
Predicting Treatment Response in Early Triple-Negative Breast Cancer
This study helps doctors predict which patients will respond best to immunochemotherapy (a combination of immune-boosting and chemotherapy drugs) for early-stage triple-negative breast cancer. By understanding your tumor better before treatment, doctors may be able to personalize your care plan.
RennesAges 18 years+ - NCT06328465Recruiting
MRI for early detection of breast cancer spread
This trial is testing a new way to use MRI scans to find breast cancer that has spread to other parts of the body early. It is for people who have had aggressive breast cancer (HER2 positive or triple negative) and finished treatment with surgery, but still have a higher risk of the cancer coming back.
MilanAges 18–75 - NCT06337084RecruitingPhase 1
Imaging test for solid tumors using MNPR-101-DFO*-89Zr
This study tests whether a new imaging agent, MNPR-101-DFO*-89Zr, can find solid tumors and measure their uPAR levels. It might help doctors better understand your cancer and guide future treatment decisions.
North Melbourne, VictoriaAges 18 years+ - NCT06342037RecruitingPhase 2
New immunotherapy options for advanced triple-negative breast cancer
This trial tests two immunotherapy drugs (atezolizumab and tiragolumab) for people with advanced triple-negative breast cancer that has not responded to standard treatments. It aims to see if this combination can shrink or slow the cancer.
Amsterdam, North HollandAges 18 years+ - NCT06347068RecruitingPhase 1
CAR-T cell therapy for triple-negative breast cancer
This trial tests a new treatment using your own immune cells, modified to target a protein called B7-H3 on triple-negative breast cancer cells. It may help if other treatments haven't worked.
Chapel Hill, North CarolinaAges 18 years+ - NCT06349642Recruiting
Testing a live tumor test for immune therapy response
This trial uses a special test on live tumor samples to see if it can predict how well immune checkpoint inhibitors (a type of immunotherapy) will work for different cancers. It may help doctors choose the best treatment for you.
Phoenix, ArizonaAges 18 years+
Hear when a new Breast Cancer Triple Negative trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer triple negative?
- Yes. Clin2 currently lists 433 recruiting breast cancer triple negative studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer triple negative trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer triple negative trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Triple Negative Breast Cancer
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Metastatic Triple-negative Breast Cancer
- Advanced Triple Negative Breast Cancer
- Triple Negative Breast Cancer (TNBC), Early Setting
- HER2-negative Breast Cancer
- Triple Negative Breast Neoplasms
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.